Merus Banner Image


  • Ticker MRUS
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Merus Logo Image
  • 51-200 Employees
  • Based in Utrecht, Netherlands
Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Their most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
4.8 / 5.0 (106)

Merus reports have an aggregate usefulness score of 4.8 based on 106 reviews.


Most Recent Annual Report

MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Merus Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!